Cannabinoids, such as cannabidivarin (CBDV) may be rare, but may also have exciting potential.
In fact, according to InMed Pharmaceuticals Inc. (NASDAQ: INM), “CBDV is one of the most studied rare cannabinoids and has been the subject of research in autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea, and pain. CBDV is also currently being studied in a number of clinical trials including autism, Prader-Willi Syndrome, and attention deficit hyperactivity disorder (ADHD).”
In addition, as noted by Rare Cannabinoid Company, “CBDV is a varin. Varins contain two fewer carbon atoms than their non-varin counterparts (THC and CBD). These differences mean that they interact with the human endocannabinoid system in different ways and have unique physiological effects.” In short, the future may be bright for companies, like InMed Pharmaceuticals, which just announced it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC.